A drug called Aviptadil shows promise in defeating the syndrome that accounts for around half of all corona-related deaths.
An Israeli company called Neurorx is currently testing a drug called Aviptadil, which could treat acute respiratory distress syndrome (ARDS), the condition responsible for around 50% of all coronavirus fatalities.
On Sunday, the U.S. Food and Drug Administration gave approval to NeuroRx for phase two trials of Aviptadil.
While this is not a complete drug approval for Covid-19-related use of the drug, it does mean the treatment is one step closer to getting the greenlight for patient use.